CG
KPTI icon

Cutler Group’s Karyopharm Therapeutics KPTI Stock Holding History

Cutler Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-321
Closed -$16K – 4297
2022
Q4 		$16K Buy
321
+293
+1,046% +$20.3K ﹤0.01% 2384
2022
Q3 		$2K Sell
28
-53
-65% -$3.96K ﹤0.01% 4234
2022
Q2 		$5K Buy
+81
New +$7.43K ﹤0.01% 3720
2020
Q2 		– Sell
-107
Closed -$30K – 4635
2020
Q1 		$30K Hold
107
– – ﹤0.01% 2051
2019
Q4 		$30K Buy
+107
New +$23.2K ﹤0.01% 1968
2017
Q4 		– Sell
-1
Closed – – 5425
2017
Q3 		$0 Sell
1
-166
-99% -$23.8K ﹤0.01% 6288
2017
Q2 		$22K Sell
167
-423
-72% -$62.6K ﹤0.01% 3323
2017
Q1 		$113K Buy
590
+508
+620% +$81.5K ﹤0.01% 1627
2016
Q4 		$11K Buy
82
+69
+531% +$9.33K ﹤0.01% 4100
2016
Q3 		$1K Sell
13
-14
-52% -$1.68K ﹤0.01% 6166
2016
Q2 		$2K Sell
27
-17
-39% -$2.21K ﹤0.01% 5679
2016
Q1 		$5K Sell
44
-209
-83% -$23.1K ﹤0.01% 4840
2015
Q4 		$50K Buy
+253
New +$54.8K ﹤0.01% 2460

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cutler Group's KPTI Position: Q1 2023 in Review

Cutler Group sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 321 shares — an estimated $16K sold.

Cutler Group first reported a position in KPTI in Q4 2015 and held it in 13 quarters. The position peaked at $113K in Q1 2017. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

  • Cutler Group reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 321 Karyopharm Therapeutics shares in Q1 2023, an estimated $16K.
  • Cutler Group first reported a position in Karyopharm Therapeutics in Q4 2015 and held it in 13 quarters.
  • Cutler Group's Karyopharm Therapeutics position peaked at $113K in Q1 2017.
  • 129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.